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Recommended by Lori Snyder
Sexually transmitted infections (STIs) and human immunodeﬁciency virus (HIV), the causative agents of acquired immunode-
ﬁciency syndrome (AIDS), are two great concerns in the reproductive health of women. Thus, the challenge is to ﬁnd products
with a double activity, on the one hand having antimicrobial/antiviral properties with a role in the reduction of STI, and on the
other hand having spermicidal action to be used as a contraceptive. In the absence of an eﬀective microbicide along with the
disadvantages of the most commonly used spermicidal contraceptive worldwide, nonoxynol-9, new emphasis has been focused
on the development of more potential intravaginal microbicidal agents. Topical microbicides spermicides would ideally provide a
female-controlled method of self-protection against HIV as well as preventing pregnancies. Nonoxynol-9, the only recommended
microbicide spermicide, damages cervicovaginal epithelium because of its membrane-disruptive properties. Clearly, there is an
urgent need to identify new compounds with dual potential microbicidal properties; antimicrobial peptides should be candidates
for such investigations. Dermaseptins and magainins are two classes of cationic, amphipathic α-helical peptides that have been
identiﬁed in the skin extracts of frogs Phyllomedusa sauvagei and Xenopus laevis. Regarding their contraceptive activities and their
eﬀect against various STI-causing pathogens, we believe that these two peptides are appropriate candidates in the evaluation of
newer and safer microbicides spermicides in the future.
Copyright © 2009 Amira Zairi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The human immunodeﬁciency virus/the causative agent
of acquired immunodeﬁciency syndrome (HIV/AIDS) pan-
demic continues its spread at a rate of over 15000 new
infections every day. Sexual transmission of HIV-1 is the
dominant mode of this pandemic spread. For the ﬁrst time
since the disease emerged in the early 1980s, about half the
42 million people now living with HIV/AIDS worldwide are
women. Worldwide, more than 90 percent of all adolescent
and adult HIV infections have resulted from heterosexual
intercourse [1]. Therefore, eﬀective strategies are needed to
reduce heterosexual and prenatal HIV transmission. In the
absence of an eﬃcient prophylactic anti-HIV therapy or
vaccine,recentemphasishasbeenplacedonthedevelopment
of intravaginal microbicidal agents capable of reducing
the transmission of HIV [2]. In addition, prophylactic
contraception is fundamentally important for HIV infected
women to prevent pregnancy and HIV transmission, espe-
cially because 80% of women with AIDS are childbearing
age. So, unwanted pregnancy is another major concern
for sexually active women [2]. Worldwide, at least half
of all pregnancies, an estimated 133 million annually, are
unintended [3].
As most of the new sexually transmitted infections (STIs)
andHIVinfectionsaretheresultofunprotectedheterosexual
intercourse, the use of barrier contraceptives like condoms
was an alternative, which aimed at controlling the spread
of these infections [3]. Studies support the fact that the
correct and consistent use of condoms protect men and
women from HIV infection and other STIs [4]. However,
drawbacks associated with such barrier methods, like men
being reluctant to use condoms and women being unable
to negotiate their use, have forced the search for better and2 Journal of Biomedicine and Biotechnology
more acceptable alternatives. One such area that is being
extensively explored is the microbicides.
Microbicides are antimicrobial products and formu-
lations. They are intended for self-administration before
sexual intercourse to protect against the transmission of HIV
and other sexually transmitted infection-causing microbes.
Microbicides can be used by women without negotiation
with their partners. This is an important characteristic
because condom-dependant protection has been unsuc-
cessful in halting the spread of HIV and other sexually
transmitted infections. The world population continues its
steep rise, leading to serious overpopulation problem in
certain regions [5]. Consumer preference studies suggest
that most women worldwide prefer a vaginal prophylactic
product with both antimicrobial and contraceptive eﬀects
[5].
At the present time, hundreds of spermicidal products
have been marketed. Most of them contain a detergent
as an active ingredient, such as nonoxynol-9 (N-9), and
benzalkonium chlorides. Some of these detergents have also
exhibited microbicidal activity in vitro [6, 7].
The spermicidal activities of these surfactants are asso-
ciated with their structural aﬃnity to the lipid membranes
[8]. However, numerous laboratory studies have now shown
that detergent spermicides do not provide any protection
against STD, and their eﬀect in preventing human immun-
odeﬁciency virus (HIV) transmission remains controversial
[9]. The major drawback of using N-9 or other currently
used surfactants is their detergent-like action on epithelial
cells and normal vaginal ﬂora [10, 11]. The repeated use
of a surfactant as a vaginal contraceptive/microbicide has
been associated with an increased risk of vaginal or cervical
infection and irritation or ulceration [11–13], detergent-
type spermicides alter vaginal bacterial ﬂora, and such
disturbance of the vaginal microbial milieu can lead to
opportunistic infections [10], which in turn increases the
chance of HIV/STI transmission.
Due to this eﬀect, it is important to identify and evaluate
a new generation of products with dual activity as antimi-
crobial/antiviral agents to reduce STIs and as spermicidal
agents for contraception. Innovative and promising sources
of candidate molecules are a group of natural components
called AMPs.
Antimicrobial peptides are an important component of
the natural defences of most living organisms against invad-
ing pathogens. These are relatively small (<10kDa), cationic
and amphipathic peptides of variable length, sequence and
structure [14–16]. During the past two decades several
AMPs have been isolated from species of all kingdoms
from insects to plants to mammals and nonmammalian
v e r t e b r a t e sa sw e l la sf r o mb a c t e r i aa n df u n g i .M o s to f
these peptides are obtained from diﬀerent sources like
macrophages, neutrophils, epithelial cells, haemocytes, fat
body, reproductive tract, and so forth. These peptides exhibit
broad-spectrum activity against bacteria, fungi, eukaryotic
parasites and/or viruses [17].
Few studies have concentrated on the action of AMPs
on sexually transmitted pathogens. The human-defensins 1–
3 have been shown to contribute to the anti-HIV-1 activity
Table 1: Sequences of dermaseptin DS4 and its derivatives.
Peptidea Sequence amino acid
b
S4 ALWMTLLKKVLKAAAKAALNAVLVGANA
S4a NH2
K4S4( 1–28) K
K4S4 (1–16)a K NH2
S4 (6–28)
aAmide.
aA dash indicates that at the speciﬁed position, the peptide contains the
amino acid identical to that of dermaseptin S4 listed above.
of CD8 antiviral factor secreted by the CD8 T cells in the
HIV infected long term precursors [18]. The activity of
protegrins against Neisseria gonorrhoeae has been studied.
Protegrins PG-1, -2, -3, and -5 are highly active against
the pathogen at low micromolar concentrations [19]. The
peptides exhibit activity against serum-resistant, serum-
sensitiveandantibiotic-resistantstrains.Yasinetal.[20]ha v e
demonstrated the susceptibility of Chlamydia trachomatis to
protegrins and defensins; while defensins are inactivated in
the presence of serum, protegrins retain their activity. A list
of peptides showing activity against STI causing pathogens is
summarized in Table 1 [14].
Apart from antimicrobial activities, few peptides have
been explored for their contraceptive potential. Subtilosin,
a bacteriocin produced by Bacillus subtilis, was shown to
eliminate the motility and forward progression of human
spermatozoa in a dose-dependent manner. Studies have
reported that this antimicrobial peptide has proven antimi-
crobial activity only against Gardenella vaginalis [21]. Reddy
et al. were the ﬁrst to report the contraceptive eﬃcacy of
nisin both in vitro and in vivo. Nisin showed a time and
dosedependenteﬀectonspermmotilitywithlimitedactivity
against STI causing pathogens [22]. Interestingly, peptides
found in the skin secretions of frogs, such as dermaseptins
and magainins, posses a potent spermicidal activity against
human sperm along with their large spectrum of action
against sexually transmitted pathogens [23–27]. This review
aims to show that these two peptides are new sources
for a promising spermicides microbicides basing on their
biological properties.
2.AntimicrobialPeptidesfromFrog’sSkin:
StructureandMechanismof Action
Genomes have evolved the capacity to respond to environ-
mental challenges with the highly focused genetic changes
[28]. The dermal glands of anuran frogs not only produce
huge amounts of biologically active peptides that are very
similar to mammalian neuropeptides as hormones [29], but
they also contain a rich arsenal of broad spectrum, cytosolic
antimicrobial peptides [30]. Many of these peptides exhibit
antibiotic, fungicidal, virucidal and tumoricidal activities
with a low cytotoxicity towards mammalian cells. These
peptides are synthesized as prepropeptides that are processed
by the removal of the signal peptide to proform and they
are stored in the large granules of the glands [31]. GlandsJournal of Biomedicine and Biotechnology 3
may release their peptide content onto the skin surface by
holocrine mechanism to provide an eﬀective and fast-acting
defense against noxious microorganisms [31]. The antimi-
crobial peptides are small, 10–50 amino acid residues long,
cationic and act in a variety of ways, however permeabilizing
and disrupting the target cell membrane is the most frequent
mechanism. According to the Shai-Matsuzaki-Huang model,
these peptides ﬁrst bind to the membrane surface up to a
critical concentration and then penetrate the membrane’s
interior [14]. This causes a decrease in the bilayer thickness
resulting in disordering the lipid chain, transient pore
formation and eventual collapse of the membrane. The
physicalnatureofthismechanismpreventsatargetorganism
from developing resistance to the peptide. Hence, these
peptideshavebeenrecognizedaspotentialtherapeuticagents
[32, 33].
The sequences of these antimicrobial peptides diﬀer
considerably from one amphibian to another. The skin of
a frog may have 10–20 antimicrobial peptides with diﬀer-
ent size, sequences, charges, hydrophobicity, tridimensional
structuresandspectrumofaction, andthis armamentdiﬀers
between frogs belonging to diﬀerent families, genera, species
or even subspecies, consequently, no two species with the
same panoply of peptide antibiotics have yet been found
[33].
This impressive divergence between and within species
means that there may be as many as 100000 diﬀerent
peptides produced by the dermatous glands of the 5000
anuran amphibians [34]. The striking variations in the
peptide sequence of frog skin antimicrobial peptides may
be exploited for discovering new molecules and struc-
tural motifs targeting speciﬁc microorganisms for which
therapeutic armamentarium is scarce. In this review, we
chose to focus on two peptides of representative amphi-
pathic α-helical antimicrobial peptides, namely magainins
and dermaseptins. Many studies have shown that these
peptides are active against various STI-causing pathogens
and HIV/herpes simplex virus both in vitro and in vivo
in addition to their contraceptive eﬃcacies. Many other
peptides from amphibian skin provide a rich source of
broad-spectrum antimicrobial peptides including some that
have antiviral activity against HIV such as caerin and
maculatin [35]. However the spermicidal activity of these
compounds has not been evaluated and no data have shown
their contraceptive eﬀect. Comparatively, dermaseptins and
magainins with their antimicrobial and spermicidal proper-
ties may certainly be beneﬁcial as a safe vaginal contraceptive
agent for the control of STIs/HIV infections.
3.DermaseptinsandMagaininsasMicrobicides
Based on the above observations that antimicrobial peptides
from frogs attack only the bacterial membranes and have
minimal interaction with the mammalian cell membranes,
the potentialities of using these molecules as an alternative
to the existing detergent-based microbicides can be seriously
considered. Various peptides are being explored for their
anti-STIandanti-HIVeﬀect.Inthisreviewwechosetofocus
on two peptides of representative amphipathic α-helical
antimicrobial peptides from frog skin namely magainins and
dermaseptins S.
4.Magainins
Magainins, also known as PGS (peptide glycine serine) [36],
are 23 amino acid long peptides isolated from the skin
of the African clawed frog Xenopus laevis [37]. Magainins
belong to a large family of amphibian amphipathic α-helical
antimicrobial peptides. These peptides have been reported
to have a wide spectrum of antimicrobial activities against
Gram-positive and Gram-negative bacteria and fungi. They
are also known to facilitate wound closure and reduce
inﬂammation [38]. Analogs of the peptide demonstrating
increased antimicrobial activity have been synthesized [37].
Arhana et al. showed that magainin-A inhibits the growth
of various strains of STI-causing pathogens, and the eﬀects
were found to be dose-dependant. The calculated MICs for
standard strains of Escherichia coli, Staphylococcus aureus,
Candida albicans and Pseudomonas aeroginosa were ranging
from 50μg/mL to 150μg/mL. It is worth noting that this
peptide did not cause red blood cells (RBC) hemolysis
up to 300μg/mL [39].The antimicrobial eﬀect might be
attributed to the disruption of the bacterial membrane.
Because of the rather non-speciﬁc mechanism toward the
bacterial membrane [39], magainin-A is active against a
b r o a ds p e c t r u mo fm i c r o b e s .T h es a m ed a t ap r o v i d e s
convincing evidence that in vitro, magainin-A is eﬀective
against some of the STI-causing pathogens [39]. Some data
demonstrated that magainins have antiviral properties, for
example, magainins I and II exhibited inhibitory action
toward Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) at
reduced and non-cytotoxic concentrations for epithelial cells
(lower than 50μg/mL) [40]. They also showed signiﬁcant
reduction of HSV plaque-forming units. The antiviral eﬀect
was enhanced when HSV was pretreated with the peptides
prior to inoculation onto Vero monolayers, suggesting a
direct eﬀect on the virion as it is shown by Egal et al. [41].
Apart from its antimicrobial activities, magainins have
also been explored for their contraceptive eﬀects. Reddy
and co-workers [24] demonstrated the spermicidal activity
of magainins-A, both in vitro and in vivo. The minimum
concentration of magainin-A required to immobilize sper-
matozoa (60 × 106–80 × 108/mL) within 20 seconds under
in vitro conditions was found to be 50μg/mL in rat and
200μg/mL in rabbits. However, in the case of monkeys the
concentrationrequiredwasﬁve-foldhighercomparedtothat
ofrabbitsandtheeﬀectwasfoundtobebothtime-anddose-
dependant.Invivostudiesonratsindicatedthatwhen200μg
of magainin-A was applied intravaginally complete arrest
of sperm mobility was observed and none of these treated
animals conceived [24]. Reddy and Manjramkar [42]l a t e r
evaluated the contraceptive eﬀect of magainins-A in rabbits
in vivo. These studies show that 1mg of magainin-A applied
intravaginally once before mating resulted in complete arrest
of sperm motility and none of the treated animals conceived.
We no longer use rabbits for the evaluation of vaginal
contraceptive potential of newer compounds, because sperm
transport through the rabbit cervix might diﬀer from that4 Journal of Biomedicine and Biotechnology
Table 2: Activity of antimicrobial peptides against sexually trans-
mitted infection causing pathogens [14].
Peptide Anti-STI/HIV activities
Rabbit-defensin mcp-1/mcp-2 Herpes simplex virus
Human-defensin-1, -2 and -3 HIV
Human-defensin T. pallidum
Rabbit-defensin NP-1 C. trachomatis
Protegrin C. trachomatis
N. gonorrhoeae
Cathelicidins T. pallidum
Cecropin (D2A21/D4E1) C. trachomatis
Mellitin HIV
Polyphemusin HIV
through the cervix of a woman [43]. Because monkeys are
the only animal with a reproductive tract similar to that
of women, they are a suitable model for postcoital testing
[43]. That’s why, the contraceptive eﬃcacy of magainin-A
was evaluated in monkeys as an in vivo model by Aranha
and associates. The results indicated that 1mg of magainin-
Aw a ss u ﬃc i e n tt oa r r e s tc o m p l e t e l ys p e r mm o t i l i t y :n o n eo f
themonkeysbecamepregnantastheyreturnedtocyclicityin
the following month [39]. They have also reported that the
repeated intravaginal administration of contraceptive doses
of magainin-A caused no adverse eﬀects on the morphology
of vaginal epithelial cells or on hematologic and serum
biochemical proﬁles [39]. The interesting observation of this
study is the selective action of magainin-A on spermatozoa,
RBCs, and vaginal cells.
5.DermaseptinsS
Dermaseptins S are a family of eight closely related peptides
that were originally isolated from the skin of a tree-dwelling,
South American frog (Phyllomedusa sauvagei). These com-
pounds are linear polycationic peptides, composed of 28–34
amino acids, which are structured in amphipathic-helices in
apolar solvents [45] .T h e ya l lh a v eac o n s e r v e dT r pr e s i d u e
atposition3,anAG(A)KAAL(V/G)G(N/K)AV(A)consensus
motif in the mid21region and a positive charge attributable
to the presence of Lys residues that punctuate an alternating
hydrophobicandhydrophilicsequence[45,46].Recently,the
identiﬁcation of new members of the dermaseptin S family
(S9–S11), diﬀerent from the current antimicrobial peptides,
has been reported after cloning from a skin secretion-derived
cDNA library [47].
Some dermaseptins show a remarkable ability to inhibit
microbial cells eﬃciently, rapidly and irreversibly without a
toxic eﬀect upon mammalian cells [48, 49]. Dermaseptins
and its analogs display cytolytic activity in vitro, generally
against a broad spectrum of host-free microorganisms,
including a series of multidrug-resistant Gram-negative
clinical isolates [48], Gram-positive strains [49, 50], espe-
cially germs responsible of genital infections such as N.
gonorrhoea [26]. In fact, antimicrobial-resistant gonococcal
infection continues to be a serious public health problem
worldwide. In recent data, Zairi et al. had described the
anti-N. gonorrhoeae activity of 5 related synthetic peptides
derived from the natural antimicrobial peptide dermaseptin
S4 (Table 2). They showed that dermaseptin S4 and its
analogs are eﬀective against 9 reference and clinical N.
gonorrhoeae strains, and that these eﬀects are dose and
time dependent. Among the diﬀerent peptides tested, they
found that dermaseptin K4-S4(1–16)a and dermaseptin K4-
S4(1–28) were the more potent to inhibit N. gonorrhoeae
growth with MIC of 10μg/mL. They also showed that
the inhibition of growth was dependent on the nature of
the peptide, and the highly charged molecules were the
most active. Dermaseptin K4-S4(1–28) showed the highest
activity with an MIC of 10 μg/mL [25]. Generally, the data
obtained from in vitro and in vivo experiments indicate that
some dermaseptin S derivatives could be very useful in a
variety of antimicrobial applications [51], especially against
opportunistic fungalinfections such as Candida, which is the
most commonly encountered fungal pathogen in the human
vagina [52]. Besides Candida, other fungal infections can
also adversely aﬀect female reproductive health. A. fumigatus
spores introduced through the vagina cause abortion in
pregnant animals [53]. In view of this consideration, Zairi
et al. had evaluated dermaseptins S4 and its analogs for their
fungicidal activity. They showed that dermaseptin S4 and its
analogs are eﬀective against clinical C. albicans strains, with a
dose-dependent manner; and the most potent one is the der-
maseptin K4S4(1–28) which had a potent fungicidal activity
at 6μg/mL [26]. Dermaseptins S are also eﬀective against
protozoa(LeishmaniamexicanaandPlasmodiumfalciparum)
[51, 54–56], yeasts as well as ﬁlamentous fungi (Aspergillus
fumigatus and Aspergillus niger)[ 46, 57]. Recently, Lorin et
al. have evaluated the anti- HIV activity of one analog of
dermaseptin K4S4(1–28) on HeLa P4-CCR5 cells as well
as on primary PBMCs and have observed that this analog
had reduced cell toxicity at high concentrations (CC50 =
16,8μM) [58]. In addition, they have also demonstrated
that dermaseptin K4S4(1–28) could be a potential anti-HIV
candidate able to disrupt viral particles before infection [58].
The same data had also showed that this peptide reduces
HIV-1 attachment to human endometrial cells (HEC-1)
and HIV-1 transcytosis through a tight HEC-1 monolayer.
Moreover, dermaseptin K4S4 presented an improved toxicity
proﬁle, although human endometrial epithelial cells are
less sensitive to the toxic eﬀect of dermaseptins than other
cells [58]. This is an important point because these cells
would be the major cell population in contact with a topical
microbicide. Thus, these molecules need to be evaluated as
new candidates with additional protection against STDs. In
addition to their antimicrobial activities, dermaseptins and
its analogs have also been explored for their contraceptive
eﬀects. Zairi and coworkers [44] elucidated the spermicidal
eﬃcacy of two dermaseptins S1 and S4, both in vitro. The
minimum concentration of DS4 required to immobilize
spermatozoa (60 × 106–80 × 108/mL) within 20 seconds
under in vitro conditions was found to be 100μg/mL on
human spermatozoa. The same data showed that sperm
motility was inhibited with various concentrations of S
at diﬀerent intervals ranging from 5 to 240 minutes.Journal of Biomedicine and Biotechnology 5
(a) (b)
Figure 1: Eﬀect of dermaseptin on sperm motility. Motile spermatozoa were preincubated in the presence or absence of increasing
concentrations of ﬁve dermaseptins derivatives for 20 seconds photomicrographics (a) control and (b) in the presence of dermaseptin;
complete sperm immobilization was seen after treatment (aggregate of spermatozoa at EC100 = 25μg/mL)). Original magniﬁcation 100 [44].
The eﬀective 100% inhibitory concentration (EC100) of S4
in 2 minutes during the sperm immobilization assay was
100μg/mL whereas the sperm immobilization of EC100 of
S1 was 200μg/mL. The presence of 0.1% chelating agent
ethylenediaminetetraacetic acid (EDTA) reduced the EC100
of S4 to 10μg/mL whereas less than a two-time enhancement
in S1 activity was observed upon combination with EDTA.
The striking phenomenon of synergistic enhancement with
EDTA, suggests that S probably aﬀects the motility of sperm
membrane by depleting cytosolic potassium and sodium
whereasEDTAchelatesextracellularcalcium[27].Theaction
ofDSsonspermmotilitywasobservedtobedosedependent.
Supplementation with pentoxifylline which is known to
enhance the motility of sperm and that with calcium, a select
sperm viability parameter did not prevent the spermicidal
action of dermaseptins [27]. Recently, Zairi et al. have been
usednormalhumansemensamplestodetectthespermicidal
activity of new compounds of dermaseptins (Figure 1)[ 44].
Inthisstudy,HeLacultureswereusedtodeterminethesafety
of compounds toward their toxicity. The data show that
all DS4 derivatives elicited concentration-dependent spermi-
cidal activity at microgram concentrations (EC100 values:
25μg/mL-1mg/mL). In cytotoxicity assay, some compounds
were found to be signiﬁcantly safer than nonoxynol-9, the
most widely used spermicide, and their activity was not
accompanied by total loss of plasma membrane integrity
as detected by ﬂuorescent microscopy [27]. Fluorescent-
binding assays were also performed to evaluate the rapidity
and the irreversibility of the sperm-immobilizing activity of
peptides. A double staining of the acrosome (with FITC-
PSA) and ﬂagellum (with anti-tubulin) of spermatozoa
incubated in the presence of non-ﬂuorescent K4S4 also
revealed a loss of the ﬂagellar membrane integrity whereas
the matrix and membrane of the acrosome remained intact
as attested by the FITC-PSA staining on sperm head
(Figure 2). By contrast, previous studies have demonstrated
that sperm exposed to 100μM of nonoxynol-9 for 3 hours
under identical conditions revealed complete loss of acro-
somal staining with FITC-lectin. The study also shows that
increasing the number of positive charges of the peptide
resulted in a reduced cytotoxicity without aﬀecting the
spermicidal eﬀects [44]. A major problem faced by the
microbicides is the pH of the vaginal tissues in which they
have to act. It is known that the vaginal pH is around 4 and
that pH rises to 8 after deposition of semen. Interestingly,
Mor and associates have shown in a recent study that
Dermaseptins S remained active in extreme conditions of
incubation such as variation of pH. This is important for
the microbicide future of such compounds because they
would retain their activity over a range of pH values
[59].
6. Conclusion
Sexually transmitted diseases pathogens are a growing
problem now and pose a serious public health threat.
To overcome the infections caused by multidrug-resistant
strains and strains resistant to all available antimicrobials,
new classes of antimicrobials should be developed. This has
been recognized by the US congress Oﬃce of Technology
AssessmentandbytheUnitedKingdomHouseofLords[25].
In addition to this burden, there has been a tremendous
increase in the number of unintended pregnancies. Prophy-
lactic contraception is fundamentally important especially
in HIV-infected women for prevention of HIV transmission
andpregnancy.Antimicrobialpeptidesrepresentapromising
class of new agents. These agents are rapidly bactericidal, and
because their action relates to physical properties, it is all
the more diﬃcult for bacteria to develop resistance to such
peptides. Moreover, it is possible to engineer their structure
with relative ease, because peptide chemistry allows a
multitude of modiﬁcations that are relatively time- and cost-
eﬀective. However although various topical applications are
considered, antimicrobial peptide notoriously lack adequate
speciﬁcity, while their relative toxicity toward red blood
cells limits their potential systemic use. Another signiﬁcant
and prohibitive factor is their relatively high cost, at least
as long as they are produced by chemical synthesis. Thus
new strategies are needed to reduce toxicity and coast
[60–62].6 Journal of Biomedicine and Biotechnology
Figure 2: Eﬀect of spermicidal dermaseptins on sperm acrosome
and ﬂagellar plasma membrane integrity. Motile sperm were
preincubated in the presence of spermicide solution (EC100 =
25μg/mL) of K4S4 and was double labelled with Fluorescein
Isothiocyanate-conjugated-Pisum sativum Agglutinin for acrosome
labelling (FITC/green) and mouse antitubulin antibody for the
ﬂagellum staining (CY3/red). The sperm heads exhibited a “dotted”
green ﬂuorescence attesting for the presence of an acrosome. At the
ﬂagellar level, we observed a loss of membrane integrity since the
anti tubulin antibodies have reached their axonemal microtubule
target [44].
Several AMPs are currently undergoing laboratory test-
ing but few have already reached clinical trials. For instance
P-113, a derivative of histatin, a human salivary peptide,
is undergoing phase I/II trials to treat oral candidiasis
aﬀecting immunocompromised patients [63]. Pexiganan,
derived from magainin, is being developed for treatment of
infectedfootulcersindiabetics[63].Thestudyisundergoing
Phase III clinical trials.
In spite of all the positive facts associate with AMPs,
there have been a few problems. Firstly, there are fewer data
available on the unknown in vitro/in vivo toxicities of the
peptide [64]. Secondly, the stability of the peptide/peptide
formulationsinvivohasnotbeenstudiedindetail.Andlastly
the cost of production of these peptides on a large scale has
been a major obstacle for quite some time. Subsequently,
these issues have been sorted out one by one. The problem of
stability has been removed by using the peptide formulations
in combination with a protease inhibit or by modifying the
amino acid composition enabling them to be recognized by
theproteases.Theproblemoflargescaleproductionhasbeen
taken care by the growing advent of recombinant synthesis
technology which is eﬀective and cheaper [14].
It is clear from the above observations that Dermaseptins
and Magainins are potential candidates for microbicides.
Studies have clearly shown the in vitro eﬃcacy of these
peptides against a lot of STI-causing pathogens. Antimi-
crobial activity against more recent isolates should be
evaluated for both peptides. As well, their activity should
be evaluated against other STDs agents, such as HSV-2,
Trichomonas vaginalis, Treponema pallidum, Chlamydia tra-
chomatis, Gardnerella, Mobiluncus, Mycoplasma, Ureaplasma
and others. Dermaseptins S and magainins may have the
potential for being used as safe and eﬀective microbicide
spermicide compounds. Further studies in this direction are
underway to establish in animal models the eﬃcacy and the
safety of these peptides alone or in combination with other
potential compounds.
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